A recently published randomized, double-blind, placebo-controlled trial found that a combination Lactobacillus strains reduced bone loss in post-menopausal women.
A recently published randomized, double-blind, placebo-controlled trial1 found that a combination Lactobacillus strains reduced bone loss in post-menopausal women. In the study, 249 women were randomly assigned to receive the probiotic consisting of Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, and Lactobacillus plantarum DSM 15313 (provided by Probi; Lund, Sweden) or placebo once daily for 12 months. At the end of the study, researchers measured the percentage change of lumbar spine bone mineral density compared to baseline.
Results showed that bone mineral density in the placebo group was significantly reduced, while no change was observed in the probiotic group. This means that the supplementation with the probiotic significantly reduced the loss of bone mineral density compared to placebo. “We are very excited about the results showing an opportunity to delay the progression of bone loss using our probiotics in this healthy population, which potentially may lead to a reduced risk for osteoporosis,” said Titti Niskanen, director R&D and clinical operations for Probi, in a press release.
“We are proud to be the first probiotic company to launch a probiotic concept within bone health,” added Tom RÃ¶nnlund, CEO of Probi. “We have experienced huge interest after the launch of the product concept to our business partners, and in just one year the concept has already been launched globally, both in Europe, the US, and Asia.”